PT  - JOURNAL ARTICLE
AU  - Ozkan Yilmaz, Huri
AU  - Saygi, Attila
AU  - Yilmaz, Adnan
AU  - Marasli, Dida
AU  - Duzgun, Yeliz
AU  - Koksal, Hulya
TI  - Relationship of T status and metastasis according to new clinical TNM staging in non small cell lung carcinoma
AID  - 10.1183/13993003.congress-2015.PA4287
DP  - 2015 Sep 01
TA  - European Respiratory Journal
PG  - PA4287
VI  - 46
IP  - suppl 59
4099  - http://erj.ersjournals.com/content/46/suppl_59/PA4287.short
4100  - http://erj.ersjournals.com/content/46/suppl_59/PA4287.full
SO  - Eur Respir J2015 Sep 01; 46
AB  - Methods: A retrospective evaluation of database from 2007 to 2009 of 136 non-small cell lung cancer patients were assessed. The variables as age, gender, smoking habits, radiological / bronchoscopic procedures, diagnostic and scanning methods for metastases were determined. Clinical staging (cTNM) was assessed in the 6th and 7th TNM staging systems.Results: Of the patients 123(90.4%) were male, 13(9.6%) were female, median age was 60.8 years (range:25-83), 41(30.1%) were squamous cell, 29(21.3%) were adenocarcinoma and 66(48.5%) were histologically undifferentiated non-small cell lung cancer. In 23 of the patients staging differed in the 7th system. 15 had “down stage”. Most striking changes were observed in stages IIIA and IIIB. Stage I remained the same. In the 6th staging system; 72(%52.9) had no metastases, 64(%47.1) had metastatic disease. 7th staging model transferred one patient to the nonmetastatic group; 73(%53.6).Of them,17(%12.5) had intrapulmonary metastases (M1a), 46(% 33.9) had distant metastases (M1b). N status did not change.Conclusion: Comparison of the 6th and 7th staging systems revealed that they were in concordance of 96.9%(r:0.968;pComparison: 6 th TNM staging system Stage IA 10(%7.4), Stage IB 13(%9.6),Stage IIA 1(% 0.7),Stage IIB 3 (%2.2), Stage IIIA 19 (%14), Stage IIIB 26 (%19.1), Stage IV 64 (%47). In 7 th TNM Revision ModelStage IA 10(%7.4), Stage IB 9(%6.6),Stage IIA 3(% 2.2),Stage IIB 5 (%3.7), Stage IIIA 28 (%20.6), Stage IIIB 18 (%13.2), Stage IV 63 (%46.3).